RetaCalc
Protocol library
SingleInvestigationalMixedVery Low confidenceSourced

Pinealon

A short peptide bioregulator studied mainly in laboratory, ageing and limited regional clinical literature. Evidence quality and formulation mapping are weak.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Community GuideSubcutaneous in guideDaily
Third-party educational bioregulator schedule

1 mg daily on days 1-5, 1.5 mg on days 6-14 and 2 mg on days 15-20

The source presents a 10-20 day community cycle. Sparse regional literature does not establish this as a replicated or product-equivalent human regimen.

View source

Evidence summary

A short peptide bioregulator studied mainly in laboratory, ageing and limited regional clinical literature. Evidence quality and formulation mapping are weak.

Protocol basis

Because the indexed literature is sparse and heterogeneous, the protocol page focuses on evidence provenance rather than retail schedules.

What remains uncertain

Independent replication, route-specific pharmacokinetics, clinically meaningful outcomes and long-term safety remain uncertain.

Warnings and contraindications

Internationally accessible controlled human evidence is limited.
Oral, intranasal and injectable claims cannot be treated as interchangeable.
Neurological and ageing claims remain insufficiently validated.